Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: A meta-analysis.

Clin Nutr

Cancer Institute, The Affiliated People's Hospital, Jiangsu University, Zhenjiang 212002, China. Electronic address:

Published: July 2024

Introduction: Cancer cachexia is a complex problem characterized by weight loss due to skeletal muscle and adipose tissue reduction. The purpose of this meta-analysis is to examine the association between cancer cachexia and adverse outcomes in patients with non-small cell lung cancer (NSCLC).

Methods: A comprehensive search was conducted in the PubMed, Web of Science, and Embase databases from their inception to January 15, 2024. Retrospective or prospective studies that investigated the cancer cachexia as a predictor of overall survival (OS), progression-free survival (PFS), overall response rate (ORR), or disease control rate (DCR) in NSCLC patients were included in this analysis.

Results: Sixteen studies, comprising 5919 NSCLC patients, were identified. The pooled prevalence of cachexia in NSCLC patients was 39%, with individual studies reporting rates ranging from 19% to 63.8%. A meta-analysis using a random effects model showed that cachexia was associated with reduced OS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.54-2.21) and PFS (HR 1.49; 95% CI 1.27-1.73). Subgroup analysis indicated that cancer cachexia significantly predicted OS, regardless of study design, NSCLC subtypes, cancer stage, definitions of cachexia, or follow-up duration. However, there was no clear association between cancer cachexia and ORR or DCR.

Conclusions: Cancer cachexia emerges is a negative prognostic factor for OS and PFS in NSCLC patients. Assessing cancer cachexia can improve risk classification for survival outcomes in this patient population.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clnu.2024.05.025DOI Listing

Publication Analysis

Top Keywords

cancer cachexia
32
nsclc patients
16
cancer
11
cachexia
10
cachexia predictor
8
adverse outcomes
8
outcomes patients
8
patients non-small
8
non-small cell
8
cell lung
8

Similar Publications

Call to Improve Coding of Cancer-Associated Cachexia.

JCO Oncol Pract

January 2025

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Cachexia is a systemic wasting syndrome prevalent in patients with cancer that significantly affects quality of life, health care costs, and therapeutic outcomes. Despite its clinical importance, cachexia is rarely formally diagnosed. This deficiency presents a challenge for effective patient management and care, health care resource allocation, and the advancement of therapeutic approaches.

View Article and Find Full Text PDF

Unlabelled: Cancer cachexia, a multifactorial condition resulting in muscle and adipose tissue wasting, reduces the quality of life of many people with cancer. Despite decades of research, therapeutic options for cancer cachexia remain limited. Cachexia is highly prevalent in people with pancreatic ductal adenocarcinoma (PDAC), and many animal models of pancreatic cancer are used to understand mechanisms underlying cachexia.

View Article and Find Full Text PDF

Introduction/background: An improved understanding of cancer-related cachexia and sarcopenia among patients with hematologic malignancies can improve their health outcomes. Patients with hematologic malignancies are affected by cancer-related cachexia and sarcopenia, but this aspect of their care is rarely studied. This review aims to increase awareness and knowledge of cancer-related cachexia and sarcopenia for patients with hematologic malignancies through a comprehensive synthesis of current research.

View Article and Find Full Text PDF

Clinical significance of cachexia index determined by bioelectrical impedance analysis in patients with gastrointestinal cancer.

Oncol Lett

March 2025

Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kansai 602-8566, Japan.

Cancer cachexia is a complex disorder characterized by skeletal muscle loss, which may influence the prognosis of patients with cancer. The cachexia index (CXI) is a new index for cachexia. The present study aimed to assess whether the CXI determined by bioelectrical impedance analysis (BIA) is valuable for predicting survival in patients with gastrointestinal cancer.

View Article and Find Full Text PDF

The treatment interventions and targets of cancer cachexia research during the past decade: a systematic review of the literature.

Ann Gastroenterol

October 2024

Department of Physiology, School of Medicine, University of Ioannina, Greece (Dimitrios Peschos, Yannis V. Simos, Christianna Zachariou, Dimitrios Stagikas, Konstantinos I. Tsamis).

Background: Cachexia is a detrimental multifactorial syndrome that has been strongly associated with cancer. A growing body of data concerning its management is being generated from the ongoing advances of experimental cancer cachexia research. This study aimed to delineate the broad landscape of cancer cachexia research, by comprehensively presenting the treatment interventions and targets of cancer cachexia during the past decade.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!